Published in Cancer Weekly, January 2nd, 2007
At the 2006 American Society of Hematology (ASH) Annual Meeting, these investigators are presenting results from five studies that tested new therapies in myeloma in order to improve effectiveness and reduce toxicity. The primary treatments being studied are the agents thalidomide (Thalomid), lenalidomide (Revlimid), and bortezomib (Velcade), that disrupt the microenvironment - the cellular habitat - of the tumor. Lenalidomide and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.